(Q40801524)

English

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jean-Michel Pawlotsky

11

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Magali Bouvier-Alias

6

object named as

Magali Bouvier-Alias

0 references

Christophe Hézode

1

object named as

Christophe Hézode

0 references

Françoise Roudot-Thoraval

8

object named as

Françoise Roudot-Thoraval

0 references

object named as

Isaac Ruiz

7

0 references

author name string

Christophe Hézode

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Stéphane Chevaliez

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Giovanna Scoazec

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Alexandre Soulier

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Anne Varaut

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Magali Bouvier-Alias

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Françoise Roudot-Thoraval

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Ariane Mallat

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Cyrille Féray

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

language of work or name

0 references

publication date

8 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

1809-1816

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Update on hepatitis C virus resistance to direct-acting antiviral agents

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Hepatitis C virus drug resistance-associated substitutions: State of the art summary

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

EASL Recommendations on Treatment of Hepatitis C 2015

1 reference

https://api.crossref.org/works/10.1002%2FHEP.28491

21 January 2018

Identifiers

10.1002/HEP.28491

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40801524&oldid=1907647848"